HLA-A2 EndoC-βH5®
Human Autoimmune Type 1 Diabetes in a Dish
HLA-A2
EndoC-βH5®
Human Autoimmune Type 1 Diabetes in a Dish
REVOLUTIONIZING AUTOIMMUNE TYPE 1 DIABETES DRUG DISCOVERY
Recapitulate beta cell specific attack after T-cell activation and unlock your innovations with a highly pathologically relevant human Type I Diabetes model
T-cell-mediated autoimmunity leading to beta cell death is a key factor in the progression of Type I diabetes. HLA-A2 EndoC-βH5® is a unique human cell model that robustly recapitulates the pathophysiology of T-cell mediated autoimmunity related to Human Type 1 diabetes. The histocompatibility antigen HLA-A*02 is a critical marker present on pancreatic beta cells of a large number of type 1 diabetic patients. HLA-A2 EndoC-βH5® is a cellular model expressing HLA-A*02 that can replicate in vitro the recognition and destruction of beta cells by CD8+ cytotoxic T cells. HLA-A2 Endoc-βH5® offers a unique solution to combine T-cell killing attack with measuring the indirect impact on insulin secretion and function loss.
FEATURES AND BENEFITS
A Pathophysiological Cell Model Recapitulating Autoimmune Human Beta Cell Attack
HLA-A2 EndoC-βH5® cells enable more accurate clinical predictions by modelling the function decrease and beta cell death in response to T-cell attack observed in Human Type 1 Diabetes
A Patho-physiological Cell Model Recapitulating Autoimmune Human Beta Cell Attack
HLA-A2 EndoC-βH5® cells enable more accurate clinical predictions by modelling the function decrease and beta cell death in response to T-cell attack observed in Human Type 1 Diabetes
QUALITY ASSURANCE
Validated
HLA-A*02
expression
Functional validation (glucose and incretin)
Negative for mycoplasma
APPLICATIONS
READOUTS
CELL MODEL RELEVANCE
NEED TO GO ONE STEP FURTHER?
Human Cell Design team of experts can offer you tailored assays and HLA-A2 EndoC-βH5® derived cell models.
